Engineering CD5-targeting CAR-NK cells from peripheral blood for the treatment of CD5-positive hematological malignancies
This study developed a controllable CD5 CAR-NK cells that exhibit high efficacy against T-cell malignancies, although further validation is necessary to assess their clinical potential.
Authors
- Haolong Lin (ORCID: https://orcid.org/0000-0002-7459-5938)
- Ning An (ORCID: https://orcid.org/0000-0001-9512-6869)
- Lingfeng Zhang (ORCID: https://orcid.org/0000-0003-4491-1554)
- Wei Mu (ORCID: https://orcid.org/0009-0005-7903-7459)
- Yicheng Zhang (ORCID: https://orcid.org/0000-0003-3643-9384)
- Tong Ge (ORCID: https://orcid.org/0000-0001-9059-8154)
- Yongkun Yang (ORCID: https://orcid.org/0000-0002-4787-4464)
Institutions
- Hubei Provincial Center for Disease Control and Prevention (CN)
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Hubei University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1186/s12967-025-06432-3
- Citations
- 9
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 9.41
Funders
- Innovative Research Group Project of the National Natural Science Foundation of China
- National Natural Science Foundation of China
- Tongji University